Global

‡ In these countries please contact our distributor

ACTICOAT in burns management

Clinically proven to help burn wound management1-3

Evidence demonstrates potential to improve outcomes and save overall treatment costs1-3

Recent evidence has demonstrated the potential for ACTICOAT Antimicrobial Barrier Dressings with nanocrystalline silver to help improve clinical outcomes, limit antibiotic use and reduce overall treatment costs for partial-thickness burn wounds1-2,4.

 

May improve patient outcomes and reduce antibiotic use in burn wound management1-2

According to evidence, adding ACTICOAT dressings to a burn wound management protocol, compared to the next best performing silver delivery system*, may achieve: 

  • Over 90% relative reduction in sepsis cases caused by Pseudomonas aeruginosa over 2 years**1.
  • Potential to reduce the use of antibiotics and help limit drug resistance**1. Further evidence demonstrated a significant reduction in antibiotic use compared to protocols including SilvadineTM5-6 and MepitelTM7.

 

Potential to reduce overall treatment costs1-2

Alongside demonstrating more Quality-Adjusted Life Years (QALYs), ACTICOAT was estimated to have the lowest overall treatment cost*1-2.

  • A 58% relative reduction in antimicrobial costs over 2 years, compared to the next best performing silver treatment**1.
  • An estimated 23% overall treatment cost reduction, compared to the next best performing silver treatment**2.  
  • ACTICOAT demonstrated an 86% probability of being more cost effective than the next best performing silver treatment2.
  • Potential to reduce length of hospital stay and associated costs2.


 

 Nherera, L., Trueman, P., Roberts, C. & Berg, L. Cost-effectiveness Analysis of Silver Delivery Approaches in the Management of Partial-thickness Burns. Wounds a Compend. Clin. Res. Pract.1–8 (2018).

 

Download the summary now

 

 

Watch our expert webcast on antimicrobial resistance and infection control, the effective use of antiseptics and a cost-efficiency meta-analysis.

 

 

Act with certainty

  • Bactericidal in as little as 30 minutes (in vitro)8-11.
  • Infection incidence potentially reduced by a relative 81%, compared to Silvadine (55% with Silvadine, 10.5% with ACTICOAT)6.
  • Reduces the instances, and minimises the progression, of wound infection through prophylactic or early application12.

 

 

  Try ACTICOAT for 2-weeks and see the difference: Request a call from your Smith & Nephew representative.

 

Helping you get CLOSER TO ZERO wound infection.


For detailed product information, including indications for use, contraindications, effects, precautions, warnings, and important safety information, please consult the Instructions for Use (IFU) prior to use.


*compared to silver-impregnated hydrofiber (SHD), silver impregnated foam (SFD) and silver sulfadiazine (SSD).
**2000-patient study, mean age 45.7 years with an 18.4% mean body area affected by burns. Conducted between 2014 and 2016 in a single centre in Poland. Comparison of silver delivery systems (Nanocrystalline silver dressings, SHD, SFD and SSD).

 

AWM-AWC-16450

 

References

1) Glik J, Łabuś W, Kitala D, et al. A 2000 patient retrospective assessment of a new strategy for burn wound management in view of infection prevention and treatment. Int Wound J. 2017 Dec 15. [Epub ahead of print]
2) Nherera L, Trueman P, Roberts C, Berg L. Cost-effectiveness analysis of silver delivery approaches in the management of partial-thickness burns. Wounds. 2018 Feb 23. [Epub ahead of print]
3) Nherera, L. M., Trueman, P., Roberts, C. D. & Berg, L. A systematic review and meta-analysis of clinical outcomes associated with nanocrystalline silver use compared to alternative silver delivery systems in the management of superficial and deep partial thickness burns. Burns 43, 939–948 (2017).
4) Woodmansey, E. J. & Roberts, C. D. Appropriate use of dressings containing nanocrystalline silver to support antimicrobial stewardship in wounds. Int. Wound J. 1–8 (2018). doi:10.1111/iwj.12969
5) Tonkin, C. & Wood, F. Nanocrystalline silver reduces the need for antibiotic therapy in burn wounds. Prim. Intent. 13, 163–168 (2005).
6) Fong, J., Wood, F. & Fowler, B. A silver coated dressing reduces the incidence of early burn wound cellulitis and associated costs of inpatient treatment: comparative patient care audits. Burns 31, 562–7 (2005).
7) Strand, O., San Migue, L., Rowan, S. & Sahlqvist, A. Retrospective comparison of two years in a paediatric burns unit, with and without acticoat as a standard dressing. Ann. Burns Fire Disasters (2010).
8) Wright et al (1998) ‘Wound management in an era of increasing bacterial antibiotic resistance: A role for topical silver treatment’, American Journal of Infection Control: 26(6):572-577.
9) Wright et al (1998) 'Efficacy of topical silver against fungal burn wound pathogens', American Journal of Infection Control (1999); 27(4): 344-350.
10) Driffield, K; ACTICOAT Flex 3 has antimicrobial activity in 30 minutes, Data on file 0810018, Smith & Nephew.
11) Driffield, K; ACTICOAT Flex 7 has antimicrobial activity in 30 minutes, Data on file 0810014, Smith & Nephew.
12) Newton (2010) Reducing MRSA bacteraemias associated with wounds. Wounds UK, Vol 6, No 1.